Lv1
20 积分 2024-02-19 加入
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
1个月前
已完结
Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial
1个月前
已完结
Missed Opportunity for Sotorasib Dose Optimization
2个月前
已完结
The Distance Toward Precision Medicine in SCLC
2个月前
已完结
Missed Opportunity for Sotorasib Dose Optimization
2个月前
已完结
The International Association for the Study of Lung Cancer Staging Project: The Database and Proposal for the Revision of the Staging of Pulmonary Neuroendocrine Carcinoma in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer
2个月前
已完结
First-Line Camrelizumab versus Placebo Plus Chemotherapy with or without Radiotherapy for Brain Metastases in Non-Small-Cell Lung Cancer: The CTONG 2003 Randomized Placebo-Controlled Trial
2个月前
已完结
Lung Cancer Screening in Low-Risk Populations: Ethical Considerations, Technological Advancements, and Socioeconomic Challenges
2个月前
已关闭
CHIPOR: gaps in recurrent ovarian cancer management
2个月前
已完结
Rucaparib versus chemotherapy for treatment of relapsed ovarian cancer with deleterious BRCA1 or BRCA2 mutation (ARIEL4): final results of an international, open-label, randomised, phase 3 trial
2个月前
已完结
皖公网安备34019202002308
